Cardiac resynchronization therapy (CRT), the application of biventricular stimulation to correct discoordinate contraction, is the only heart failure treatment that enhances acute and chronic systolic function, increases cardiac work, and reduces mortality. Resting myocyte function also increases after CRT despite only modest improvement in calcium transients, suggesting that CRT may enhance myofilament calcium responsiveness. To test this hypothesis, we examined adult dogs subjected to tachypacing-induced heart failure for 6 weeks, concurrent with ventricular dyssynchrony (HF dys ) or CRT. Myofilament force-calcium relationships were measured in skinned trabeculae and/or myocytes. Compared with control, maximal calcium-activated force and calcium sensitivity declined globally in HF dys ; however, CRT restored both. Phosphatase PP1 induced calcium desensitization in control and CRT-treated cells, while HF dys cells were unaffected, implying that CRT enhances myofilament phosphorylation. Proteomics revealed phosphorylation sites on Z-disk and Mband proteins, which were predicted to be targets of glycogen synthase kinase-3b (GSK-3b). We found that GSK-3b was deactivated in HF dys and reactivated by CRT. Mass spectrometry of myofilament proteins from HF dys animals incubated with GSK-3b confirmed GSK-3b-dependent phosphorylation at many of the same sites observed with CRT. GSK-3b restored calcium sensitivity in HF dys , but did not affect control or CRT cells. These data indicate that CRT improves calcium responsiveness of myofilaments following HF dys through GSK-3b reactivation, identifying a therapeutic approach to enhancing contractile function.
Introduction
For the past 30 years or more, the quest to develop treatments that directly improve systolic performance of the failing heart while also conferring long-term survival benefits has been met with disappointment (1) . Agents that stimulate the β1-adrenergic receptor or enhance cyclic AMP (e.g., PDE3 inhibitors) work in the short term, but have worsened chronic outcomes. This has led some to question whether safe and effective systolic therapy for the failing heart is an oxymoron (2) . A counterexample that forced this conclusion to be reconsidered is the device treatment known as cardiac resynchronization therapy (CRT). CRT restores coordinate contraction in heart failure (HF) patients who also have ventricular dyssynchrony due to conduction abnormalities. Its improvement of systolic function occurs within 1 beat (3) and is associated with negligible or even reduced myocardial oxygen consumption, indicating improved chamber efficiency (4, 5) . While dyssynchrony is an independent risk factor in patients with HF, successful CRT reduces mortality (6, 7) , perhaps to levels even below those of HF patients without dyssynchrony (8, 9) .
The effects of CRT were initially attributed to its impact on chamber mechanoenergetics (3) . However, recent studies by our and other laboratories have revealed many changes at the cellular and molecular levels as well, and these present a unique profile for CRT unmatched by other HF treatments to date. For exam-ple, marked heterogeneity of regional gene expression is reversed (10) , the cytoprotective Akt pathway is stimulated and is coupled with reduced apoptosis (11, 12) , calcium handling and associated ultrastructure of the sarcoplasmic reticulum improve (13) (14) (15) , mitochondrial efficiency and ATP synthase activity are enhanced via a redox switch (16) , ion channel function regulating the action potential is improved (17, 18) , and resting as well as β-adrenergicstimulated myocyte function are markedly restored by a mechanism involving regulators of G protein signaling (19, 20) . Interestingly, while CRT substantially improves resting myocyte function throughout the ventricle, this is not consistently matched by increases in the calcium transient (17, 20) , suggesting CRT may also enhance myofilament responses to calcium. This is intriguing, as small molecule HF therapies that target the myofilament are of growing interest (1, (21) (22) (23) .
Accordingly, we tested the hypothesis that myofilament function is depressed in dyssynchronous HF (HF dys ) and improved by CRT. Given that myofilament Ca 2+ sensitivity is modulated by thinfilament protein phosphorylation (24) (25) (26) and prior data reveal CRT can modify several pertinent kinases and phosphatases (11) , we speculated that CRT affects myofilament protein phosphorylation as an underlying mechanism. To investigate this, we studied a canine model combining tachypacing-induced HF with dyssynchrony or CRT (19, 20) . Heart failure was induced by 6 weeks of rapid pacing. HF dys combined left bundle branch ablation with atrial tachypacing. For resynchronized HF (CRT), the same procedure was used for the initial 3 weeks, followed by rapid biventricular stimulation. These and other model modifications utilized in this study are summarized in Figure 1 . Echocardiographic and hemodynamic features of these models have been reported (19, 20) and are summarized for the current set of animals in Supplemental Table 1 (supplemental material available online with this article; doi:10.1172/ JCI69253DS1). Trabecular and/or myocyte sarcomere function were assessed and proteomics used to identify phosphorylation changes linked to enhanced myofilament function from CRT.
Results
CRT globally restores myofilament function. Steady state force-calcium data for skinned myocytes from the LV lateral endocardium are shown in Figure 2A . Myofilament function was markedly depressed in HF dys , with maximum calcium-activated force (F max ) declining nearly 50% compared with normal controls (controls: 37.9 ± 3.5 mN • mm -2 , n = 15 myocytes from 6 dogs, HF dys : 21.5 ± 3.0 mN • mm -2 , n = 16 myocytes from 6 dogs, P < 0.001; Figure 2B ). HF dys also exhibited Ca 2+ desensitization as quantified by a rise in EC 50 (controls: 2.34 ± 0.13 μM, HF dys : 3.04 ± 0.17 μM, P = 0.003; Figure 2B ). CRT remarkably and completely restored both parameters of myofilament function to normal (F max : 40.3 ± 2.60 mN • mm -2 , EC 50 : 2.18 ± 0.13 μM, n = 16 myocytes from 7 dogs, P < 0.001 vs. HF dys , P = NS vs. controls).
Contractile dyssynchrony with a left-bundle delay results in marked differences in regional stress (high in lateral wall due to early stretch/late contraction, lower in septum/RV with early contraction/ late stretch). To determine whether this influenced CRT modulation of myofilament function, we studied skinned trabeculae from the RV free wall (Figure 2 , C and D) and single myocytes from the LV septum (Supplemental Figure 1 ). Both preparations revealed similarly depressed sarcomere function, as found in the LV free wall for HF dys , and marked improvement with CRT. Thus, the precise nature of cyclical regional stress or strain temporal pattern was not a primary determinant of myofilament changes in either condition.
We next tested whether CRT alters crossbridge mechanoenergetics by simultaneously assessing isolated fiber bundle ATP utilization and force development. The ATP required to achieve a given crossbridge tension (tension cost) and the rate of force redevelopment upon sudden stress release (crossbridge kinetics, k tr ) were similarly depressed in HF dys and CRT ( Figure 2 , E and F). The number of attached crossbridges during tension development, assessed by dynamic stiffness, was unchanged from control values by either HF dys or CRT ( Figure 2G ). Thus, CRT did not affect the mechanoenergetics of the crossbridge.
Importance of resynchronization. The recovery of myofilament function with CRT was not merely due to contraction being synchronous, as sarcomere function was also markedly depressed in HF that was always synchronous (HF sync ). As with HF dys , F max was much reduced in HF sync (21.08 ± 3.22 mN • mm -2 , P < 0.001 vs. controls and CRT, P = NS vs. HF dys , n = 15 myocytes from 5 dogs; Supplemental Figure 2 ). However, whereas HF dys cells displayed a rise in EC 50 , those from HF sync had a lower value (i.e., sensitized to Ca 2+ ; 1.70 ± 0.11 μM, P = 0.007, 0.036, 0.003 vs. controls, CRT, and HF dys , respectively).
These data indicated that improved myofibrillar function required preexisting dyssynchrony that was subsequently reversed. To test this concept further, we modified the HF sync model to include a 2-week period of dyssynchrony induced by RV pacing during weeks 3 and 4 (AVA model [atrial, ventricular, atrial pacing]) (19) . Compared with HF sync , AVA myocardium had a greater F max (AVA: 23.4 ± 1.9 mN • mm -2 , n = 10 trabeculae from 5 dogs, HF sync : 16.5 ± 1.9, n = 22 trabeculae from 8 dogs, P < 0.05 vs. HF sync , P = NS vs. controls) and EC 50 returned to normal control values ( Figure 3 , A and B).
CRT involved direct ventricular myocardial stimulation that might have triggered improved myofibrillar function. To test this, we studied an alternative "CRT" model that used rapid RV free-wall pacing (no left bundle branch block [LBBB] was performed) to generate dyssynchrony and HF and then subsequently resynchronized the hearts by switching to rapid atrial pacing, avoiding the need for any direct ventricular stimulation. The results for this model (V3A3) were very similar to those with CRT ( Figure 3 , C and D), indicating direct pacemaker stimulation of the LV was not required.
Altered maximum force is due to myocyte hypertrophy. The decline in F max (normalized to myocyte cross-sectional area [CSA]) in both HF dys and HF sync could result from proteolytic cleavage of myofibrillar proteins such as troponin I (TnI) (27) or isoform switching (e.g., troponin T [TnT]; ref. 28 ). However, silver stained 1D gels and Western blots revealed neither protein cleavage products nor isoform switching in these models (Supplemental Figure 3 ). Normalization of force to CSA is generally performed, since one assumes bigger cells will have more force-generating units. Yet while control, HF dys , and CRT cells had similar raw (nonnormalized) peak force, CSA differed markedly ( Figure 4D ). Specifically, HF dys had twice the CSA of controls, but this was reversed by CRT (controls: 251 ± 36, HF dys : 465 ± 64, CRT: 268 ± 44 μm 2 , P < 0.012, 0.015 HF dys vs. controls and CRT, respectively; Figure 4 , A and B). To rule out potential selection bias in cells for which physiological data had been measured, we measured CSA from all cells in a given microscopic field (n = 150 myocytes from 3 dogs). This confirmed that HF dys myocytes were enlarged and that CRT reversed this (P < 0.001, Figure 4C ). In trabeculae, F max was also depressed ( Figure 2C ), but CSA was similar among the models ( Figure 4E ).
Figure 1
Timeline of pacing protocols in each of the canine models: control, HFdys, CRT, HFsync, V3A3 (3 weeks RV pacing to induce dyssynchrony, 3 weeks atrial pacing to restore synchrony), and AVA (HFsync with 2 weeks of induced transient dyssynchrony via RV pacing). The HFdys and CRT models receive LBBB via radio-frequency ablation. After a 1-week recovery period from the pacemaker implant, each pacing protocol lasts 6 weeks before the animal is sacrificed.
Ca 2+ sensitization is mediated by myofilament phosphorylation. Figure 5A displays example force-calcium data from RV trabeculae prior to and following incubation with the phosphatase PP1. Dephosphorylation did not change F max in any group (Supplemental Figure 4A ). However, EC 50 increased (desensitized) in control (ΔEC 50 : 1.09 ± 0.22 μM, n = 6) and CRT (ΔEC 50 : 0.70 ± 0.23 μM, n = 5) trabeculae, but was unaltered in HF dys (ΔEC 50 : -0.06 ± 0.14 μM, n = 5, P < 0.003, 0.04 vs. controls and CRT, respectively; Figure 5B ). PP1-induced calcium desensitization without a change in F max was also observed in V3A3 and AVA models, indicating phosphorylation was involved with their improved Ca 2+ sensitivity as well (Supplemental Figure 4) .
Ca 2+ sensitivity is regulated by phosphorylation of the regulatory thin-filament proteins TnI, TnT, myosin-binding protein C (MyBPC), and myosin light chain 2 (MLC2). Table 1 lists the phosphorylation sites involved, their respective influence on Ca 2+ sensitivity, and directional changes in each due to HF (if reported). Previous studies show that phosphorylation of TnI at S22/S23 (PKA) (29) and S43/S45 (PKC) (30, 31) desensitize, whereas phosphorylation at T144 (PKC) (31, 32) or S150 (AMPkinase, PAK1) (33, 34) increase sensitivity (the latter only reported in vitro). Overall, TnI phosphorylation declined similarly in HF dys and CRT ( Figure 5C ), and reduced S22/S23 targeting was directly confirmed by immunoblot (Supplemental Figure 5 ). This supports a Ca 2+ sensitization effect (as opposed to desensitization observed in HF dys , e.g., Figure 2A ). MyBPC phosphorylated at S273/S282/S302 (35) (by PKA and other kinases; ref. 36) or MLC2 phosphorylation at S15/S19 increases Ca 2+ -sensitivity (37) . These posttranslational modifications (PTMs) declined to the same extent in both failure models ( Figure 5 , D and E) and so could not be responsible for the differences between HF dys and CRT. Finally, TnT phosphorylation at T206 (38) (PKC) or S278/ T287 (39) (Rho-kinase II) is linked to sensitization, but these sites were not altered in the models ( Figure 5F ).
Figure 2
CRT globally restores myofilament function. (A) Force-calcium data and fitted curves for myocytes from the LV lateral wall for controls (black circles, n = 15 myocytes from 6 dogs), HFdys (white triangles, n = 16 myocytes from 6 dogs), and CRT (gray squares, n = 16 myocytes from 7 dogs). Inset: force normalized to Fmax to visualize the change in calcium sensitivity. (B) Fmax is decreased by approximately 50% in HFdys and restored by CRT. HFdys causes desensitization to calcium (increase in EC50), but is restored to control levels with CRT. (C) Force-calcium data and fitted curves for RV trabeculae muscles for control (black circles, n = 14 muscles from 8 dogs), HFdys (white triangles, n = 24 muscles from 13 dogs), and CRT (gray squares, n = 18 muscles from 10 dogs). Inset: force normalized to Fmax to visualize the change in calcium sensitivity. (D) Fmax and EC50 were altered in the RV to an extent similar to that in the LV. (E) Tension cost, the ratio of ATPase activity to developed tension, was reduced in both HF models, and not recovered by CRT. (F) Cross-bridge turnover dynamics (ktr) were also reduced in the HF models and not restored by CRT. (G) Finally, stiffness was not affected in any of the groups. *P < 0.05 vs. control; # P < 0.05 vs. HFdys by 1-way ANOVA.
The lack of differential changes in all of these sites was further confirmed by mass spectrometry (Supplemental Table 2 ) and/or 2D differential gel electrophoresis (Supplemental Figure 6 ).
Z-disk and M-band proteins are phosphorylated by CRT; role of GSK-3β. Given that the known phospho-protein targets did not appear to be involved, we turned to mass spectrometry to broadly interrogate the myofibrillar subproteome. A total of 1187 phosphorylation sites on 166 myofilament and myofilament-associated proteins were detected, and CRT significantly altered 33 of these sites (P < 0.05, quantified by normalized spectral counts; Table 2 ). Based on the PP1 results, we focused on residues exhibiting increased phosphorylation with CRT, yielding 15 sites on 13 proteins ( Table 2 and Supplemental . Figure 6A summarizes this analysis. The majority of modified sites resided in proteins expressed in the Z-disk and M-band regions. Though such pro-teomic analysis can bias toward highabundance or high-molecular weight proteins (e.g., titin or obscurin), our analysis identified only a single site on each, supporting response specificity. We used in silico analysis of the individual phosphorylation sites (using NetPhosK and Human Protein Reference Database) to identify kinase consensus sequences based on the phosphorylation targets ( Table 2 ) and found that glycogen synthase kinase-3β (GSK-3β) and p38 MAPK targeted the most sites. We previously found that p38 was activated by HF dys and suppressed by CRT, whereas GSK-3β was less active in HF dys and activated by CRT (11) . Therefore, we focused on the latter kinase as a potential contributor.
To determine whether the phosphorylated residues increased by CRT were indeed targets of GSK-3β, we performed a second mass spectrometry experiment. The myofilament subproteome obtained from HF dys dogs was incubated with 18 O-labeled ATP in the absence or presence of recombinant active GSK-3β for 30 minutes at 30°C and prepared for proteomic analysis. Table 3 lists the phosphorylated amino acid residues targeted by GSK-3β that were also found to increase with CRT. Four of the 7 GSK-3β sites revealed by in silico analysis were confirmed, and 4 additional sites altered by CRT but not predicted by bioinformatics were revealed as GSK-3β targets as well. This supports the notion that GSK-3β converts a subset of the HF dys phospho-proteome into one similar to CRT.
To test whether GSK-3β myofilament phosphorylation could be responsible for the sensitizing affect, myofilament function was examined in HF dys myocytes before and after exposure to recombinant active GSK-3β for 30 minutes. Treated cells exhibited a decline in EC 50 similar to that observed with CRT (P < 0.001 HF dys vs. pretreatment, P = NS versus CRT; Figure 6 , B and C). In 
Figure 4
The apparent decrease in Fmax is due to myocyte hypertrophy. (A) Skinned myocytes from controls, HFdys, and CRT. (B) CSA (calculated by measuring both width and depth and assuming an elliptical shape) was significantly increased in HFdys, but restored to normal levels in CRT. (C) The unbiased approach also showed that HFdys myocytes were hypertrophied, and this was reversed by CRT (n = 150 myocytes from 3 dogs per group). (D) Fmax is typically normalized to CSA, but if it is not, the myocytes generate the same amount of force between the groups, indicating that the force producing capacity of the myocytes is not altered; they are just bigger. (E) There was no difference in trabeculae muscle size, despite the fact that a decrease in Fmax was also observed. This suggests that there are fewer myocytes in HFdys in a constant area of myocardium. *P < 0.05 vs. control; # P < 0.05 vs. HFdys by 1-way ANOVA.
contrast, myocytes from CRT hearts were unchanged by GSK-3β, consistent with existing stimulation of this pathway and underlying sensitization. Control myocytes were also unaffected by GSK-3β. F max was unaltered by GSK-3β in any of the groups, agreeing with our finding that F max is primarily affected by myocyte geometry in these models.
To determine whether differential effects on calcium sensitivity were specific to GSK-3β, we exposed HF dys and CRT myocytes to PKA and Akt, 2 kinases involved in GSK-3β signaling. As expected, PKA modestly increased F max while decreasing calcium sensitivity (increased EC 50 ), and it did so similarly in both groups (no interaction between group and treatment) (Supplemental Figure 22 ). This result is consistent with reduced TnI and MyBPC phosphorylation at PKA-targeted sites in both HF dys and CRT ( Figure 5, C and D) . Although Akt is a recognized upstream kinase modulator of GSK-3β, myocytes incubated with Akt exhibited no change in F max or EC 50 in either group (Supplemental Figure 23, A and B) , supporting an alternative pathway. While Akt treatment did not detectably increase phosphorylation of any proteins in the myofilament fraction (Supplemental Figure 23C) , it did in whole-cell lysate (serine 9 Time course and offsetting effects on Ca 2+ sensitivity by dyssynchrony. The observation that Ca 2+ sensitivity declined with HF dys but rose with HF sync suggested differential phosphorylation might mediate dysfunction due to dyssynchrony. To test this further, we examined the time course of changes in both models, performing studies at 3 weeks in myocytes isolated from endocardial biopsies. After 3 weeks of pacing, both models showed a similar decline in F max ; however, there was dissociation of Ca 2+ sensitivity (Figure 7, A and B) , with a fall in EC 50 in HF sync (sensitization), but no change in HF dys . There were no further declines in HF sync at week 6, whereas EC 50 rose in HF dys . These data support an early sensitization factor in both models that is gradually offset by desensitization solely in HF dys ( Figure 7C ). This could relate to the decline in TnI phosphorylation by week 3 that remained similarly reduced at week 6 in both models (Figure 7 , D and E). However, the ratio of phospho/total GSK-3β was unaltered at either time in HF sync , whereas there was a gradual rise in the ratio in HF dys (enzyme inactivation) concordant with the gradual increase in EC 50 . These results support the notion that phospho/total GSK-3β may serve as a biomarker for dyssynchrony with relevance to contractile function.
Discussion
We report that HF dys exhibits depressed myofilament responsiveness to calcium in both early and late activated regions and that CRT restores this to virtually normal levels. The mechanism appears to involve reactivation of GSK-3β and phosphorylation of Z-disk and M-band proteins as well as reversal of myocyte hypertrophy with depressed maximal force-per myocyte CSA. Similar myofilament functional improvement is attained if synchronous failing hearts are subjected to a period of dyssynchrony, confirming the key role of recoordinating contraction to this response. These results identify a mechanism by which CRT enhances systolic function beyond that previously attributed to chamber mechanics (3), adrenergic regulation (19, 20) , and calcium homeostasis (17) . The findings further suggest new approaches for improving myofilament function in the broader HF population. The table provides the direction of a change in calcium sensitivity due to phosphorylation, the direction that phosphorylation is modified by HF, and how this in turn impacts calcium sensitivity. Dyssynchrony generates regional heterogeneity of wall stress in the ventricle, with areas of increased or decreased load corresponding, respectively, to late or early activation. Despite these differences, similar depression of myofilament function and its recovery by CRT were observed in both regions. This indicates that the precise pattern of stress (or strain) is less important than the presence of spatial heterogeneity of these properties. Global chamber modifications with both dyssynchronous and resynchronized HF are not unique to myofilament function, but have also been observed with respect to antiapoptosis signaling coupled to Akt and GSK-3β (11), ion channel function (17) , and adrenergic regulation (19) .
Successful CRT converts hearts with a prior history of dyssynchrony into those with coordinate contraction. This temporal sequence was central to enhancing myofibrillar function just as it was to improving myocardial responsiveness to β-adrenergic stimulation (19) . Failing hearts that were never dyssynchronous (HF sync ) had worse myofilament function than those that were resynchronized, the latter including CRT, V3A3, and AVA models. The presence of dyssynchrony differentially affected calcium sensitivity.
Enhanced Ca 2+ sensitivity as observed with HF sync has been reported in human HF sync (40) , whereas reduced Ca 2+ sensitivity as with HF dys was compatible with experimental data from failing hearts with myocardial infarction (24) . These differences were previously attributed to difficulties in preserving the phosphorylation state of myofilament proteins in human explant tissue samples (41) . However, the current data controls for this (dogs do not receive different medications and tissue is harvested almost immediately after sacrifice), suggesting instead that regional stress-strain heterogeneity, as occurs with electromechanical dyssynchrony or regional infarction, plays a role. Disparities in Ca 2+ sensitivity between HF sync and HF dys may underlie the greater adverse risks (increased morbidity and mortality) observed in HF patients with dyssynchrony (42, 43) .
The AVA study that exposed hearts to temporary dyssynchrony also increased F max over HF sync and suggests what we believe is a novel translational approach for improving myofibrillar function in the failing heart. For example, patients with HF sync might benefit from a defined exposure to RV pacing-induced dyssynchrony that is then terminated to activate ameliorative changes. Alter-
Figure 6
Increased phosphorylation at GSK-3β sites in CRT mediated the calcium-sensitizing effect. (A) Schematic of the cardiac sarcomere showing Z-disk (green), titin (gray) thick filament (blue), M-line (black), and thin filament (red). The proteins (and sites) that were identified as increased with CRT are shown, with their best-known localization. Asterisks indicate matches with GSK-3β consensus sequence. (B) Representative force-calcium relationships in controls (top), HFdys (middle), and CRT (bottom) before (solid lines) and after GSK-3β treatment (dashed lines). (C) There was a calcium-sensitizing effect of GSK-3β in HFdys (n = 8), bringing it to the same level as controls and CRT. GSK-3β had no effect on controls (n = 5) or CRT myocytes (n = 8). *P < 0.05 vs. control baseline value.
natively, patients receiving CRT might benefit from periods of suspending biventricular pacing. This phenomenon may reflect a form of dyssynchrony-induced "preconditioning" (44), establishing molecular signaling, such as GSK-3β inactivation, that triggers subsequent changes after hearts are subsequently resynchronized. The precise molecular pathways involved, the optimal duration of dyssynchrony exposure needed to achieve them, and the longevity of any ameliorative myofilament effects upon resynchronization remain to be fully determined.
F max declined with HF dys and was restored by CRT. Neither myofibrillar protein degradation nor isoform shifts were detected, but HF dys myocytes were larger than controls. Myocyte hypertrophy with dyssynchrony could result from heightened regional stresses (systolic and diastolic) that occur in early-and late-contracting regions. HF dys amplifies p38 and CaMKII activity that can stimulate hypertrophy (45) , and CRT restores both to normal (11) . Cell hypertrophy is expected to elevate force due to more myofibers, yet maximal force was unchanged, implying force per fiber declined in HF dys and was restored to normal by CRT. Similar results have appeared in several prior studies, though they were not specifically highlighted. For example, in HF patients treated with LV assist devices (LVAD), F max (normalized to cell area) was one-fourth that of healthy control levels prior to LVAD insertion and doubled after LVAD insertion (46) . However, myocyte size was 4 times greater than normal before LVAD insertion and fell by 50% after LVAD insertion (cells got smaller). Multiplying normalized F max by cell size in each case yielded the same maximal force value in all 3 groups. Another example comes from a study of myocardial infarction: normalized F max was lower in the infarcted samples (compared with controls), but cell size was larger. When F max was not adjusted for cell area (unnormalized), it was similar between the groups (24) . Similar findings were reported in myocytes from RV hypertrophy (47) . There are multiple possible explanations for unchanged nonnormalized F max with myocyte hypertrophy, including (a) myofibrils are not added despite an increase in cell size, (b) new myofibrils are added, but they function poorly, or (c) overall per-myofiber function is depressed. Which of these possibilities is responsible, however, remains unknown.
Modulation of Ca 2+ -sensitivity (EC 50 ) by phosphorylation, as was found relevant to CRT, commonly involves the thin-filament proteins. Modifications in TnI, MyBPC, and MCL2 were all documented in the present study, but were similar in both HF dys and CRT. CRT also depresses TnI phosphorylation at S165, T180, and S198 (48) , but these all go in the opposite direction to explain a PP1 effect. Rather than revealing alternative thin-filament targets, our proteomic analysis identified Z-disk and/or M-band proteins. Both of these regions are nexuses for mechanosensing, and while their possible involvement with contractile-protein regulation is less well characterized, they anchor thin and thick filaments, respectively, and localize enzymes that modify myofilament proteins. They are central to maintaining sarcomere geometry, integrating force, and transmitting tension, so it is reasonable that they could also modulate Ca 2+ -dependent contraction. For example, modifying the Z-disk proteins Cap-Z (reducing expression) or muscle LIM protein (MLP) (acetylation) increases calcium sensitivity (49, 50) . In skeletal muscle, reducing Z-disk or M-band stiffness reduces calcium sensitivity (51), while genetic mutations in Z-disk proteins result in cardiomyopathy associated with Z-disk destabilization (52) and/or changes in myofilament stiffness and Ca 2+ response (53) .
Treating HF dys myofilament samples with active GSK-3β recapitulated both the sensitization of HF dys myofibers and key features of the CRT phospho-proteomic footprint ( Table 2 and Table 3 ), including sites that were not predicted by bioinformatics. GSK-3β has been previously only shown to modify MyBPC and thereby affect contraction kinetics (54) . The current data are the first, to our knowledge, to reveal its effects on calcium sensitivity, but this was unique to myocytes from HF with dyssynchronous contraction. GSK-3β phosphorylation was not due to Akt, as the latter kinase had no effect on myofibrillar phosphorylation or function despite its capacity to phosphorylate cytosolic GSK-3β.
Among the various myofilament GSK-3β targets, the more intriguing include tensin-1 (S1274) and filamin-C (S2228), as these modifications were not detected in the absence of kinase incubation. Tensin-1, classically known as a focal adhesion protein, binds to the Z-disk in cardiomyocytes in response to stress (55) . Filamin-C is an actin-binding protein, localized within the Z-disk. Mutations in filamin-C cause dilated cardiomyopathy (DCM), and a splice variant is associated with heart disease (56) . Other potential candidates include obscurin (S4809) and actinbinding LIM protein 1 (abLIM1) (S421). Obscurin is present in the Z-disk and M-band, where it is tethered to titin and myomesin, respectively, and it contains a kinase domain as well. abLIM1 binds to actin at the Z-disk, and the phosphorylation site that was altered by CRT (S421) is in the region thought to bind to actin (57) . None of these proteins or their phosphorylated forms have been previously associated with changes in myofilament function under normal or pathological conditions. LGsFGSITR Present Labeled
Labeled sites incorporated the 18 O-labeled ATP. Predicted target indicates whether the phosphorylation site was identified as a possible substrate for GSK-3β using in silico analysis (see Table 2 ). For each group, n = 3 dogs were pooled. A Low localization probability of the phospho-serine, indicating a nearby serine could also be a possible target.
Our study leaves unanswered the exact identity of which GSK-3β target or targets are responsible for improved calcium sensitivity by CRT. The M-band and Z-disk are highly structured regions in the sarcomere, and protein substitution cannot be achieved by diffusion in skinned cell preparations. Thus, direct confirmation will require site mutagenesis and genetic modifications. Ongoing efforts to translate the canine model to the mouse will be an important next step to dissecting the pathways, since gene delivery and/or transgenic models are more practical. This will also allow genetic knockdown of GSK-3β to confirm the myofilament substrates. The canine model is highly translational but poses its own limitations, since tachypacing is required throughout the protocol to generate HF. This impacts global functional parameters such as stroke volume or ejection fraction, which decline at fast heart rates independently of contractility changes (58) . This likely explains why such variables and chamber volumes were similar among the models despite differences in myofilament contractile function, whereas the less load-sensitive parameter dP/dt max /IP (IP, instantaneous developed pressure at time of dP/dt max ) was improved by CRT.
The myofilament is rapidly becoming an attractive target for enhancing systolic function in HF (21) . Over the past 10 to 20 years, investigators have explored drugs to improve Ca 2+ responsiveness, though such efforts have yet to yield a broadly successful therapy. A new approach to enhancing myofilament ATPase activity was reported (21) and is currently in clinical trials (23) , though chronic efficacy remains unknown. In contrast, CRT is already a successful treatment with documented long-term benefits on morbidity and mortality. The present analysis attempts to reverse engineer it, unmasking an unanticipated yet striking improvement in myofilament function by a mechanism likely to be both safe and effective. At present, we do not know whether there is a single Z-disk or M-band protein target or whether several are involved, but the results strongly suggest GSK-3β as a key signaling kinase, revealing what we believe to be a novel role for this enzyme in the sarcomere. The ability to mimic Ca 2+ -sensitizing effects of CRT by augmenting GSK-3β activation in HF dys myocytes and/or exposing the heart to brief periods of sustained dyssynchrony may help forge new paths for HF treatment.
Methods
Canine pacing models. Details of the canine models have been previously reported (19, 20) . All dogs except controls received a pacemaker implant (Medtronic). HFdys and CRT models both received left bundle branch radio-frequency ablation at time of pacemaker implant, while in 3 other models (HFsync, AVA,
Figure 7
Time course of function and phosphorylation during dyssynchrony and HF. (A) Endocardial biopsies taken at the 3-week time point (controls, n = 8, HFdys 3 weeks: n = 11, HFsync 3 weeks: n = 5, HFdys 6 weeks: n = 17, HFsync 6 weeks: n = 18 myocytes) showed that Fmax decreased steadily over the entire 6-week protocol. (B) Calcium sensitivity was altered in HFsync by 3 weeks, with no changes between 3 and 6 weeks. However, HFdys was unaltered at 3 weeks, but desensitized between 3 and 6 weeks. (C) When the sensitizing temporal effect of decreased TnI phosphorylation is added to the desensitizing temporal effects of decreased GSK-3β activity, it recapitulates the observed phenotype in B. (D) S22/S23 TnI phosphorylation was decreased in both HFdys and HFsync by 3 weeks, with no additional decrease between 3 and 6 weeks (n = 5 per time point). (E) Phospho GSK-3β was unchanged in HFsync over the 6 weeks, but linearly increased in HFdys; P < 0.01 via multivariate regression analysis. *P < 0.05 vs. controls; # P < 0.05 vs. HFsync at 3 weeks.
Mass spectrometry. Six HFdys and 6 CRT LV lateral wall myocardial samples were myofilament enriched (1 mg protein in 8M urea, 1% SDS) and digested in trypsin (Promega Corp.). Alternatively, myofilament-enriched samples from HFdys tissue were split into 2 equal parts, one incubated in ATP γ-P 18 O-labeled (Cambridge Isotope Laboratories Inc.) relax buffer, and the second incubated in labeled relax buffer plus 4 μg of GSK-3β (n = 3). The labeled relax buffer contained a 1:1 ratio of unlabeled and 18 O-labeled ATP. The samples were incubated at 30°C for 30 minutes.
All myofilament samples were fractionated by strong-cation exchange to decrease sample complexity and increase sequence coverage. Each fraction was then individually phospho enriched using titanium oxide affinity chromatography. Phospho-peptides were analyzed on an Agilent 1200 Nano-LC system (Agilent Technologies) connected to an LTQ-Orbitrap mass spectrometer (Thermo Scientific) equipped with a nanoelectrospray ion source.
All raw MS/MS data was searched using the Sorcerer 2-SEQUEST algorithm (Sage-N Research). Additional analysis was done using Scaffold PTM (v1.1.3; Proteome Software). For studies with GSK-3β treatment, MS data were searched using SEQUEST, with labeled phosphorylation that included an additional 6.01-Da shift due to the 18 O-labeled phosphate group. Kinase consensus amino acid sequences were predicted using Net-PhosK (http://cbs.dtu.dk/services/NetPhosK/) and the Human Protein Reference Database (hprd.org).
Further details are provided in the Supplemental Methods.
Statistics. Values were compared between the groups using 1-way ANOVA, with post hoc comparisons made with the Holm-Sidak method using Sig-maPlot (v11, Systat Software Inc.). MS was quantified based on label-free spectra counts. Normalized spectral counts were compared using Student's t test. GSK-3β phosphorylation relationships were tested using multivariate regression analysis using Systat (Systat Software, Inc.). All tests were 2-tailed with a P value of less than 0.05 considered significant. All values are presented as mean ± SEM.
Study approval. All animal studies were approved by the Johns Hopkins Animal Care and Use Committee and performed by trained personnel.
